Rigel Pharmaceuticals RIGL Accrued research and development
Accrued research and development at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:IncreaseDecreaseInAccruedResearchAndDevelopmentLiability.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's accrued research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's accrued research and development?
- Rigel Pharmaceuticals (RIGL) reported accrued research and development of $218K in Q1 2026.
- How has Rigel Pharmaceuticals's accrued research and development changed year-over-year?
- Rigel Pharmaceuticals's accrued research and development decreased by 62.1% year-over-year, from $575K to $218K.
- What is the long-term trend for Rigel Pharmaceuticals's accrued research and development?
- Over 2 years (2021 to 2023), Rigel Pharmaceuticals's accrued research and development has grown at a -12.6% compound annual growth rate (CAGR), from $5.5M to -$4.2M.
- What does accrued research and development mean?
- Represents the change in liabilities recognized for research and development activities that have been incurred but not yet paid. This metric tracks the timing differences between R&D work performed and the actual cash outflow to vendors or partners. It is a vital indicator of the company's R&D spending momentum and short-term liquidity management.